Article
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Annals of internal medicine - 4 Nov 2014
Osinusi Anu, Kohli Anita, Marti Miriam M, Nelson Amy, Zhang Xiaozhen, Meissner Eric G, Silk Rachel, Townsend Kerry, Pang Phillip S, Subramanian G Mani, McHutchison John G, Fauci Anthony S, Masur Henry, Kottilil Shyam
Abstract excerpt
BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. However, sofosbuvir plus ribavirin therapy is associated with relapse in 15% to 30% of patients with HCV GT-1. Neither the mechanism of relapse nor the optimal re-treatment strategy for these patients is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.